Eugia US Recalls One Lot of Injectable Vancomycin Due to Glass Particles
Eugia US LLC is voluntarily recalling one lot of Vancomycin Hydrochloride for Injection USP, 1.25g/Vial-30mL. The recalled drug has lot number 3VM26026A with an expiration date of July 2028. The company issued the recall after finding a glass particle inside a vial. Eugia shipped the affected lot to wholesalers across the United States between September 2, 2026, and September 15, 2026. Vancomycin is an injectable antibiotic used in hospitals and clinics to treat bacterial infections such as septicaemia and endocarditis. Injecting glass particles can block blood vessels, cause blood clots, trigger allergic reactions, or lead to organ damage and death. Eugia stated it has not received any reports of injury or illness related to this lot. The U.S. Food and Drug Administration posted the alert on November 9, 2026. Facilities with this lot should stop using it and quarantine the product.
What was announced
On November 6, 2026, Eugia US LLC announced a voluntary recall of lot 3VM26026A of Vancomycin Hydrochloride for Injection USP. The U.S. Food and Drug Administration published the safety notice on November 9, 2026. The recalled product comes in 30 mL single-dose vials with NDC 55150-471-01 on the vial label and NDC 55150-471-10 on the printed carton. The expiration date listed on the product is JUL 2028.
Eugia distributed the lot to wholesalers nationwide from September 2, 2026, through September 15, 2026. The recall began after glass particulate matter was identified inside a vial.
What it means
Hospitals, pharmacies, and healthcare providers holding lot 3VM26026A must stop using it immediately. Eugia instructs facilities to quarantine the product and contact Qualanex to arrange returns or replacements.
Using an injection containing glass particles carries serious health risks. Particulate matter in blood vessels can block blood flow, create blood clots in the lungs, irritate local veins, or cause organ damage and death. Patients with compromised organ function, infants, and neonates face higher risks.
Patients who suspect they experienced an adverse reaction should contact their healthcare provider. Eugia reported that it has not received any reports of adverse events linked to this recall. Quality problems or adverse reactions can also be reported directly to the FDA MedWatch program.
What the announcement does not tell us
The announcement does not state how the glass particle entered the vial during manufacturing or packaging. It does not clarify whether other lots produced around the same time were inspected or affected.
The notice also does not reveal how many total vials are in lot 3VM26026A, nor does it specify how many vials have already been administered to patients since distribution began in September 2026.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA MedWatch Safety Alerts’s own. Always check the original before acting on anything here.
FOR IMMEDIATE RELEASE –November 06,2026 – East Windsor, New Jersey, Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) to the hospital/healthcare facility/user level due to the pre
Opens www.fda.gov
More from FDA MedWatch Safety Alerts
- Game Changer Products LLC Issues Voluntary Nationwide Recall of 10 Day Forecast Capsules Due to the Presence of Undeclared Sildenafil and Acetaminophen12 November 2026
- Early Alert: Intersurgical Inc. Removes 22mm Smoothbore breathing tubes and systems10 November 2026
- Early Alert: Arrow International Removes Products Containing Spring Wire Guide Components10 November 2026
- Heart Pump Controller Recall: Abiomed Removes Automated Impella Controllers (AIC)9 November 2026
- MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication9 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.